查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1751299

心臟生物標記市場規模、佔有率、趨勢分析報告（按類型、應用、最終用途、地區、細分市場預測），2025 年至 2030 年

Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, CK-MB, Myoglobin, BNP and NT-proBNP, Others), By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

心臟生物標記市場的成長和趨勢：

根據 Grand View Research, Inc. 的最新報告，全球心臟生物標記市場預計到 2030 年將達到 511.9 億美元，預測期內的複合年成長率為 14.1%。

急性冠狀動脈症候群（ACS）盛行率的不斷上升，以及生物標記技術的進步，預計將推動市場成長。人們對心臟疾病早期診斷和預後的認知不斷提高，預計將進一步推動市場發展。

根據克利夫蘭診所的報告，美國有超過1800萬成年人患有心臟疾病。胸痛是急診就診最常見的原因之一。心臟病是美國的主要死亡原因之一，估計每41秒就有一人心臟病發作。心臟生物標記在診斷急性冠狀動脈綜合症（ACS）中發揮重要作用，並有助於更快地做出治療決策。

生物標記在風險分層和急性冠狀動脈症候群診斷中的應用日益廣泛，推動了相關需求。不健康的生活方式正在增加急性冠狀動脈症候群和心肌梗塞的盛行率。即時診斷（PoC）的日益普及促進了心臟標記的使用，並推動了細分市場的創新。醫院和即時診斷（PoC）中心臟生物標記應用的模式轉移，歸因於近期心肌肌鈣蛋白I和心肌肌鈣蛋白敏感性檢測的發展趨勢。

心臟生物標記市場報告重點

  • 按類型分類，肌鈣蛋白預計在 2024 年佔據最大收益佔有率，超過 35.5%，這得益於其在心血管疾病診斷中的廣泛應用。
  • 根據應用，急性冠狀動脈症候群部分預計將在 2025 年至 2030 年間以最快的複合年成長率成長。
  • 根據最終用途，實驗室測試領域在 2024 年佔據市場主導地位。
  • 由於北美發達的醫療保健體係有利於採用心臟生物標記作為診斷和預後工具，預計 2024 年北美將在全球市場佔據主導地位。
  • 心臟生物標記市場的主要參與者包括雅培、Quidel Corporation、西門子醫療有限公司、F. Hoffmann-La Roche Ltd、丹納赫、BIOMERIEUX、Bio-Rad Laboratories Inc、Randox Laboratories Ltd、Creative Diagnostics、Life Diagnostics 等。
  • 新型檢測方法的不斷湧現是未來幾年預計推動市場成長的主要因素之一。例如，邁瑞於2023年10月推出了兩種高靈敏度的心臟生物標記檢測方法：hs-cTnI檢測和NT-proBNP檢測。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章心臟生物標記市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 心臟生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 心臟生物標記市場：管道分析

第4章：心臟生物標記市場：按類型估計和趨勢分析

  • 細分儀表板
  • 心臟生物標記市場：變異分析
  • 全球心臟生物標記市場規模與趨勢分析（2018-2030）
  • 肌鈣蛋白
  • CK-MB
  • 肌紅蛋白
  • 不可逆電穿孔消融
  • BNP 和 NT-PROBNP
  • 其他

第5章：心臟生物標記市場：按應用的估計和趨勢分析

  • 細分儀表板
  • 心臟生物標記市場：變異分析
  • 全球心臟生物標記市場規模與趨勢分析（2018-2030）
  • 急性冠狀動脈症候群
  • 心肌梗塞
  • 鬱血性心臟衰竭衰竭
  • 其他

第6章：心臟生物標記市場：依最終用途的估計和趨勢分析

  • 細分儀表板
  • 心臟生物標記市場：變異分析
  • 全球心臟生物標記市場規模與趨勢分析（2018-2030）
  • 實驗室測試
  • 就地檢驗

第7章：心臟生物標記市場：區域估計與趨勢分析

  • 區域市場儀表板
  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場：關鍵要點
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
  • 公司簡介
    • Abbott
    • Quidel Corporatio
    • Siemens Healthcare Gmbh
    • F. Hoffmann-La Roche Ltd.
    • Danaher
    • BIOMERIEUX
    • Bio-Rad Laboratories, Inc.
    • Randox Laboratories Ltd.
    • Creative Diagnostics
    • Life Diagnostics
Product Code: GVR-1-68038-083-5

Cardiac Biomarkers Market Growth & Trends:

The global cardiac biomarkers market is anticipated to reach USD 51.19 billion by 2030 and is anticipated to expand at a CAGR of 14.1% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.

According to the report by Cleveland Clinic, more than 18 million adults in the U.S. were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S., and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.

The rising adoption of biomarkers in risk stratification and diagnosis of acute coronary syndrome is increasing the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making the use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin.

Cardiac Biomarkers Market Report Highlights:

  • In terms of type, the troponin segment held the largest revenue share of over 35.5% in 2024 owing to its high usage in cardiovascular disease diagnosis
  • Based on application, the acute coronary syndrome segment is expected to grow at the fastest CAGR during 2025 - 2030
  • In terms of end use, laboratory testing segment dominated the market in 2024
  • North America dominated the global market in 2024 owing to the presence of a developed healthcare system that facilitates easier adoption of cardiac biomarkers as a tool for diagnosis and prognosis
  • Key players operating in the cardiac biomarkers market include Abbott, Quidel Corporation, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, Danaher, BIOMERIEUX, Bio-Rad Laboratories Inc, Randox Laboratories Ltd, Creative Diagnostics, Life Diagnostics
  • The rise in the availability of novel assays is one of the major drivers anticipated to boost market growth in the upcoming years. For instance, in October 2023, Mindray launched two highly sensitive cardiac biomarkers assays, hs-cTnI Assay, and NT-proBNP Assay, to diversify its portfolio in cardio biomarkers to provide enhanced cardiovascular disease care.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type
    • 2.2.2. Application
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cardiac Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market outlook
    • 3.1.2. Related/ancillary Market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cardiac Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Cardiac Biomarkers Market : Pipeline Analysis

Chapter 4. Cardiac Biomarkers Market : Type Estimates & Trend Analysis

  • 4.1. Type Segment Dashboard
  • 4.2. Cardiac Biomarkers Market: Type Movement Analysis
  • 4.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Troponin
    • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. CK-MB
    • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Myoglobin
    • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Irreversible Electroporation Ablation
    • 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. BNP AND NT-PROBNP
    • 4.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cardiac Biomarkers Market : Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Cardiac Biomarkers Market: Application Movement Analysis
  • 5.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Acute Coronary Syndrome
    • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Myocardial Infarction
    • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Congestive Heart Failure
    • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cardiac Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Cardiac Biomarkers Market: End Use Movement Analysis
  • 6.3. Global Cardiac Biomarkers Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Laboratory Testing
    • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.5. Point of Care Testing
    • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cardiac Biomarkers Market : Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing Market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.6. Norway
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Norway Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.7. Sweden
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Sweden Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework/ reimbursement structure
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Denmark Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Japan
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Japan Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. China Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Quidel Corporatio
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Siemens Healthcare Gmbh
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Danaher
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. BIOMERIEUX
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Bio-Rad Laboratories, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Randox Laboratories Ltd.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Creative Diagnostics
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Life Diagnostics
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 3 North America cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 5 North America cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 6 U.S cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 8 U.S cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 9 Canada cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 12 Europe cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 14 Europe cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 16 Germany cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 17 Germany cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 UK cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 20 UK cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 UK cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 23 France cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 France cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Italy cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 26 Italy cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Italy cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Spain cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 29 Spain cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Spain cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 31 Denmark cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 32 Denmark cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Denmark cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Sweden cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 35 Sweden cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Sweden cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Norway cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 38 Norway cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Norway cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 44 Japan cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 45 Japan cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 46 Japan cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 China cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 48 China cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 49 China cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 50 India cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 51 India cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 52 India cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 53 Australia cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 54 Australia cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 55 Australia cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Thailand cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 57 Thailand cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 58 Thailand cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Korea cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 60 South Korea cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 61 South Korea cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 62 Latin America cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 63 Latin America cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 64 Latin America cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Latin America cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 66 Brazil cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Brazil cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Mexico cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Mexico cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Argentina cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 Argentina cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Middle East and Africa cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 Middle East and Africa cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 77 Middle East and Africa cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Middle East and Africa cardiac biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 79 South Africa cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 80 South Africa cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 85 UAE cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 86 UAE cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait cardiac biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 89 Kuwait cardiac biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait cardiac biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Cardiac biomarkers: Market outlook
  • Fig. 8 Cardiac biomarkers: Competitive insights
  • Fig. 9 Parent market outlook
  • Fig. 10 Related/ancillary market outlook
  • Fig. 11 Penetration and growth prospect mapping
  • Fig. 12 Cardiac biomarkers market driver impact
  • Fig. 13 Cardiac biomarkers market restraint impact
  • Fig. 14 Cardiac biomarkers market strategic initiatives analysis
  • Fig. 15 Cardiac biomarkers market: Type movement analysis
  • Fig. 16 Cardiac biomarkers market: Type outlook and key takeaways
  • Fig. 17 Troponin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 CK-MB market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Myoglobin market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 BNP and NT-proBNP market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cardiac biomarkers market: Application movement analysis
  • Fig. 23 Cardiac biomarkers market: Application outlook and key takeaways
  • Fig. 24 Acute coronary syndrome market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Myocardial infarction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Congestive heart failure market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Other applications market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Cardiac biomarkers market: End use movement analysis
  • Fig. 29 Cardiac biomarkers market: End use outlook and key takeaways
  • Fig. 30 Laboratory testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Point of care testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pain management market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Vaccine delivery market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Other end use market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Global cardiac biomarkers market: Regional movement analysis
  • Fig. 37 Global cardiac biomarkers market: Regional outlook and key takeaways
  • Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)